- In April 2024, Nigeria introduced the Men5CV vaccine, providing protection against five strains of the Neisseria meningitidis bacteria (meningococcus) responsible for meningitis. Nigeria is the first country globally to launch this vaccine, which is recommended by the World Health Organization (WHO). The rollout of the Men5CV vaccine marks a significant advancement in combating meningitis, offering broader protection than previous vaccines by covering strains A, C, W, Y, and X with a single shot. In comparison, existing vaccines in Africa were only effective against strain A
- In April 2020, the U.S. approved Sanofi’s MenQuadfi conjugate vaccine for the prevention of meningitis in children aged 2 years and older. This approval allowed Sanofi to expand its product portfolio and contributed to the growth of the meningitis prevention market
